Biologics growth transforms API market

The global market for APIs is being transformed as biologic ingredients make up an increasing share of the overall $78 billion market, with biologic ingredients set to grow 12 percent to 15 percent per year to reach $12 billion by 2011. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.